Unlocking the Potential of IGKV2D-29 as a Drug Target and Biomarker

Target Name: IGKV2D-29

NCBI ID: G28882

Other Name(s): Immunoglobulin kappa variable 2D-29 | IGKV2D29 | immunoglobulin kappa variable 2D-29 | A2a | A2c

Unlocking the Potential of IGKV2D-29 as a Drug Target and Biomarker

Immunoglobulin kappa variable 2D-29 (IGKV2D-29) is a single-chain variable region antibody that plays a critical role in various physiological processes in the human body. It is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract, and has been implicated in a number of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. As a result, IGKV2D-29 has generated significant interest as a potential drug target and biomarker.

Drug Target Potential

The drug development process typically begins with the identification of a potential drug target. In the case of IGKV2D-29, its unique structure and various functions make it an attractive candidate for drug targeting. IGKV2D-29 has been shown to interact with various protein partners, including the transcription factor nuclear factor E2F1, which plays a crucial role in cell proliferation and survival.

Furthermore, IGKV2D-29 has been shown to promote the growth and survival of cancer cells, which raises concerns about its potential as a cancer drug. Therefore, IGKV2D-29 could be a useful drug target for cancer treatment.

Biomarker Potential

IGKV2D-29 has also been shown to serve as a potential biomarker for various diseases. For instance, IGKV2D-29 has been used as a biomarker to diagnose autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. In these disorders, the immune system attacks the body's own tissues, leading to inflammation and joint damage.

Additionally, IGKV2D-29 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, IGKV2D-29 could be a valuable biomarker for the early detection and development of these debilitating diseases.

Conclusion

In conclusion, IGKV2D-29 is a promising drug target and biomarker due to its unique structure and various functions. Its ability to interact with nuclear factor E2F1 and promote the growth and survival of cancer cells make it an attractive candidate for drug targeting. Furthermore, IGKV2D-29 has also been shown to serve as a potential biomarker for various diseases, including autoimmune disorders and neurodegenerative diseases. Further research is needed to fully understand the potential of IGKV2D-29 as a drug target and biomarker.

Protein Name: Immunoglobulin Kappa Variable 2D-29

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets